Bloom Energy's $2.6 Billion Vote of Confidence Collides With a Rare Earth Legal Storm
Published on 08/07/2026 at 14:14 | Redaktion boerse-global.de
The fuel-cell maker's stock has been a study in extremes: up more than 550 percent over the past year, yet weighed down by short-seller allegations and a mounting pile of shareholder litigation. On Friday, shares climbed 3.87 percent to €206.50, a bounce that underscores just how sharply the market's mood can swing on this particular name. The central question hanging over Bloom Energy is whether it is the indispensable power provider for the artificial-intelligence boom or simply the latest momentum trade with cracks beneath the surface.
The Bull Case Is Getting Harder to Ignore
The company's AI ambitions crystallized this week with an expanded partnership with MiTAC Computing Technology, which will see Bloom install a fuel-cell microgrid at a new AI server manufacturing campus in Fremont, California. That deal pushes the company's contracted AI-related capacity to roughly 250 megawatts spread across nearly two dozen customers. Management says every major US hyperscaler and more than a dozen AI-focused neoclouds and labs have now validated Bloom's technology.
The financial backing matches the commercial momentum. In late July, Industrial Development Funding, Oaktree, MUFG Bank and Morgan Stanley committed a combined $2.6 billion to finance Bloom projects — a clear signal that institutional capital sees the demand story as credible, not speculative.
The numbers back that confidence. On July 28, Bloom reported record second-quarter revenue of $1.065 billion, up 165.5 percent year over year, with product revenue surging 215 percent. Adjusted earnings per share came in at $0.78, nearly double the $0.40 consensus estimate. Adjusted gross margin expanded to 34.3 percent from 28.2 percent a year earlier. On a GAAP basis, the picture was equally strong: gross margin climbed to 33.4 percent from 26.7 percent, operating income swung from a $3.5 million loss to a $182.2 million profit, and net income landed at $196.3 million, or $0.62 per share, against a year-ago loss of $0.18 per share. Operating cash flow of $226 million and free cash flow of $175 million suggest the profitability is real rather than an accounting artifact, while a $2.7 billion cash pile provides ample cushion for whatever legal battles lie ahead.
Management responded by lifting full-year guidance, now projecting 2026 revenue between $3.9 billion and $4.2 billion, adjusted earnings per share of $2.55 to $2.85, and operating income of $800 million to $900 million.
The Short-Seller Attack and Its Legal Aftermath
The trouble began in early July when Hunterbrook Media published a report titled "Bloom's Big Lie," alleging the company sources scandium — a critical component in its fuel-cell chemistry — from China through indirect channels, including direct shipments to Delaware and intermediaries in Thailand, Japan and South Korea. The report claimed 37 measured installations fell below promised efficiency thresholds after a median of just 20 months. The stock dropped nearly 6 percent in the immediate aftermath.
Speaking of supply-chain transparency — ensuring every component and process in your own operations is properly documented is just as critical for your business. A free toolkit walks you through risk assessments with 41 ready-to-use templates and checklists, helping you stay ahead of compliance gaps before they become liabilities. Download the free Risk Assessment Toolkit
The legal fallout has been swift. On August 4, multiple firms — including Robbins LLP, DJS Law Group, Kaplan Fox and Wolf Haldenstein — filed class actions covering the period from February 27, 2025, through July 8, 2026, alleging Bloom misrepresented its dependence on Chinese-sourced scandium. A separate suit from Rosen Law Firm, filed Wednesday, accuses the company of misleading investors between early 2025 and mid-2026. Investors seeking lead plaintiff status have until September 28 to step forward.
Adding to the unease, director John T. Chambers sold 55,000 shares on May 28 at $297.69 apiece, a planned transaction worth roughly $16.37 million. Such sales are routine and legally unproblematic, but in the current climate, every insider trade gets extra scrutiny.
Analysts Trim Targets Without Abandoning the Thesis
Wall Street's response to the quarter was telling: price targets came down, but ratings largely held. Mizuho upgraded the stock from Neutral to Outperform on July 30 while cutting its target from $285 to $242, citing stronger operational execution and margin expansion. JP Morgan reaffirmed its Overweight rating the previous day but trimmed its target from $346 to $314 — still the highest on the Street. The message is consistent: the business is delivering, but the valuation after such a dramatic run gives even bullish analysts pause.
A Powerful Counterweight
Brookfield Asset Management has emerged as a significant vote of confidence. On June 30, the firm expanded its financing framework for AI-related power projects from $5 billion to $25 billion — a fivefold increase since October 2025 — a move that signals deep conviction from a capital partner known for rigorous due diligence.
Reading the Tape
The stock's technical position tells its own story. After a 52-week run that at one point showed a gain of 553.69 percent in dollar terms — or 164.89 percent on a one-year basis in German trading — the shares closed Thursday at €198.80, down 2.07 percent. They now sit roughly 33 to 36 percent below the recent 52-week high of €308.50, depending on the trading venue, while still trading about 26 percent above the 200-day moving average. That gap between peak and current levels captures the volatility inherent in a stock caught between a booming order book and unresolved questions about supply-chain transparency.
Just as investors scrutinize Bloom's disclosures, regulators and inspectors are paying closer attention to how UK businesses document their workplace hazards. A free Health & Safety toolkit gives you risk assessments, checklists and toolbox talks aligned with current UK requirements — so you can demonstrate compliance with confidence. Get the free Health & Safety Toolkit
For now, the operational story is winning. The $2.6 billion financing commitment, the hyperscaler validations and the record quarter all point to a company executing at a high level. But the September 28 lead-plaintiff deadline looms, and the outcome of the litigation could determine whether Bloom's valuation climbs back toward its highs or whether the trust deficit proves a lasting drag. Investors in this name are buying not just fuel cells for data centers, but the turbulence of an industry still learning to power the AI revolution.
